Loading
Life sciences · Journal article
Dermatology and Therapy · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This large survey documents patient-reported dermatologic effects associated with GLP-1RA use and weight loss, including skin sagging, hair loss, and facial volume loss that increase with greater weight loss, alongside reported improvement in inflammatory and hormonally driven skin conditions. The findings are descriptive and hypothesis-generating but lack clinical validation, mechanistic insight, and adjustment for confounders such as baseline skin quality, age, and weight loss speed.
Voluntary cross-sectional survey. Patients of a virtual cardio-kidney-metabolic treatment program; eligible for inclusion if they completed the voluntary survey on dermatologic and physical changes.. Intervention: GLP-1 receptor agonist (GLP-1RA) therapy for weight management, or non-GLP-1RA therapy, or combination therapy.. Compared with: Stratified comparison by weight loss category (<10%, 10–20%, >20%) and medication type (GLP-1RA vs. non-GLP-1RA vs. combination).. n = 1,226. Not stated..
Among respondents with >20% body weight loss (n=325): skin sagging 72% (95% CI 67–76), hair loss 52% (95% CI 47–58), decreased facial volume 50% (95% CI 45–55), reduced strength 33% (95% CI 28–38) Among respondents with 10–20% weight loss (n=395): skin sagging 44% (95% CI 39–49), hair loss 30% (95% CI 26–35), decreased facial volume 37% (95% CI 33–42), reduced strength 19% (95% CI 16–23) Among respondents with <10% weight loss (n=380): skin sagging 15% (95% CI 12–19), hair loss 17% (95% CI 13–21), decreased facial volume 13% (95% CI 10–16), reduced strength 9% (95% CI 7–13)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians prescribing GLP-1RAs for weight loss should counsel patients on dermatologic effects that increase with greater weight loss—particularly skin laxity, hair shedding, and facial volume loss—while noting that improvements in inflammatory and hormonally driven skin conditions may also occur. These patient-reported findings warrant controlled study to clarify mechanism, incidence, and clinical significance independent of weight loss alone.
Large voluntary survey with patient-reported outcomes showing dermatologic effects associated with GLP-1RA weight loss, but lacks a controlled comparator group and relies on unvalidated self-report without clinical adjudication.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians prescribing GLP-1RAs for weight loss should counsel patients on dermatologic effects that increase with greater weight loss—particularly skin laxity, hair shedding, and facial volume loss—while noting that improvements in inflammatory and hormonally driven skin conditions may also occur. These patient-reported findings warrant controlled study to clarify mechanism, incidence, and clinical significance independent of weight loss alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
INTRODUCTION: With the surge in use of glucagon-like peptide 1-receptor agonists (GLP-1RAs) for weight management, "Ozempic Face," one of the dermatologic effects describing facial hollowing, sinking cheeks, and skin laxity, has drawn public attention. While substantial media discourse has surrounded certain dermatologic effects, patient-reported data is needed to more accurately characterize them. This study identifies patient-reported changes in skin, hair, and nails associated with weight management treatment with GLP-1RAs, including the frequency of dermatologic effects relative to weight loss. METHODS: Our study was conducted through an IRB-approved, voluntary, anonymous survey developed via collaboration between obesity medicine physicians and dermatologists. The survey was then distributed to patients of a virtual cardio-kidney-metabolic treatment program. Responses (n = 1226) were sorted by the percent body weight lost and categorized by medication regimen (glucagon-like peptide 1-receptor agonists; GLP-1RA, nonGLP-1RA, or combination therapy). Patients reported dermatologic and overall physical changes. RESULTS: Dermatologic effects were reported more frequently with greater weight loss. Of respondents reporting greater than 20% body weight loss, (n = 325) 233 (72%; 95% CI 67-76) reported skin sagging, (n = 325) 170 (52%; 95% CI 47-58) reported hair loss, (n = 325) 163 (50%; 95% CI 45-55) reported decreased facial volume, and (n = 325) 107 (33%; 95% CI 28-38) reported reduced strength. Of respondents reporting 10-20% weight loss, (n = 395) 172 (44%; 95% CI 39-49) reported skin sagging, (n = 395) 119 (30%; 95% CI 26-35) reported hair loss, (n = 395) 147 (37%; 95% CI 33-42) reported decreased facial volume, and (n = 395) 76 (19%; 95% CI 16-23%) reported reduced strength. In comparison, of respondents reporting less than 10% weight loss, only (n = 380) 57 (15%; 95% CI 12-19) reported skin sagging, (n = 380) 65 (17%; 95% CI 13-21) reported hair loss, (n = 380) 48 (13%; 95% CI 10-16) reported decreased facial volume, and (n = 380) 35 (9%; 95% CI 7-13) reported reduced strength. The frequency of adverse patient-reported outcomes increased significantly with increasing percentage of body weight loss. Cochran-Armitage trend testing identified significant positive trends across the < 10%, 10-20%, and > 20% body weight loss categories for skin sagging (Z = 15.22), hair loss (Z = 9.91), decreased facial volume (Z = 10.70), and reduced strength (Z = 7.85), with P values of < 0.001. Among survey respondents on at least one GLP-1RA medication therapy, improvement was reported in certain preexisting inflammatory and hormonally driven skin conditions, including hidradenitis suppurativa (n = 15), 13 (87%; 95% CI 60-98); acanthosis nigricans (n = 12), 9 (75%; 95% CI 43-93); psoriasis (n = 47), 22 (47%; 95% CI 32-62); acne (n = 41), 17 (41%; 95% CI 27-57); eczema (n = 64), 17 (27%; 95% CI 17-39); hirsutism (n = 14), 4 (29%; 95% CI 10-56); seborrheic dermatitis (n = 16), 4 (25%; 95% CI 8-52); and skin tags (n = 57), 14 (25%; 95% CI 15-37). CONCLUSIONS: This large analysis of patient-reported outcomes suggests that greater weight loss, which often occurred with GLP-1RA treatment regimens versus other weight management therapies, was associated with higher reports of negative aesthetic impacts, most notably skin laxity, facial volume loss, and hair shedding, although with improvement in preexisting inflammatory and hormonally driven dermatological conditions. This calls for further studies to determine the potential mechanisms and incidence behind patient-reported outcomes associated with significant weight loss on GLP-1RA medications.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.